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Abstract 
Objectives
West syndrome is a severe epileptic encephalopathy of young age. 
It is characterized by a clinico-electrical triad of infantile epileptic 
spasms, regression or arrest of psychomotor development, and 
hypsarrhythmia. In the last two decades, the large progress in the 
development of newer antiepileptic drugs has allowed us to have 
a vast choice of treatment options to control spasms, although they 
often fail to do so. Thus, there is a need to explore other treatment 
options.
Materials & Methods
Subjects in this open-labelled randomized control trial were included 
newly diagnosed children of age between 3 months and 5 years of 
both genders. A total of 52 children were recruited and randomized 
into two groups: an intervention group (n=30) and a non-intervention 
group (n=22). Magnesium sulphate was provided for the intervention 
group but not for the non-intervention one. Both groups received 
the rest of the treatments, including adrenocorticotropic hormone 
and antiepileptic drugs. The follow-up period was three months, at 
the end of which a per-protocol analysis was performed.
Results
There was no significant difference in seizure control and 
neurodevelopmental outcome between both groups, but 
electroencephalogram significantly improved in the intervention 
group compared to the control. Also, the clinical response was 
better in patients with normal initial serum magnesium levels in the 
intervention group (p=0.003) than in other patients.
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Conclusion
Magnesium supplementation may be helpful in children with West 
syndrome. 
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Introduction
West syndrome (WS) is a severe epileptic 
encephalopathy of young age. It is characterized 
by a clinico-electrical triad of (i) infantile epileptic 
spasms, (ii) regression or arrest of psychomotor 
development, and (iii) hypsarrhythmia (1). 
Hypsarrhythmia is a slow, chaotic background 
with multifocal spikes of high voltage on 
electroencephalography (EEG) (2). This classical 
triad comprises variations in age of onset 
ranging from one month to 4 years: spasms that 
may be single, asymmetrical, or combined with 
focal seizures; asymmetrical, synchronous, or 
fragmented hypsarrhythmia; and psychomotor 
function that may be delayed, deteriorated, or 
normal (1). WS is one of the most typical infantile 
epileptic syndromes seen in pediatric neurology 
clinics with an age of onset mostly between 3-12 
months, peaking around 5 months of age with a 
male preponderance (3). 
There is no agreement on the optimum treatment 
for WS. In the last two decades, the large progress 
in the development of newer antiepileptic drugs 
has enabled us to have a vast choice of treatment 
options to control spasms, although they often fail 
to do so (4,5). Thus, there is a need to explore other 
treatment options.
Various studies have shown lower serum levels 
of magnesium in children with epilepsy (6-13). 
Magnesium has antiepileptic and neuroprotective 
properties due to the antagonizing effect of the 
N-methyl-d–aspartate (NMDA) receptor (14). 
Magnesium is useful in various refractory epilepsies 
(15-17). However, there is a dearth of studies, 
especially randomized control trials (RCTs), on the 
role of magnesium in children with WS. Therefore, 
the present study aimed to examine the effect of 
magnesium on children with WS regarding seizure 
control, neurodevelopmental outcome, and EEG 
improvement through an RCT study design.
Materials & Methods
This open-labeled randomized controlled clinical 
trial was conducted at the pediatrics department 
of a government tertiary care teaching hospital of 
Northern India from Feb 2019 to March 2020 in 
children with WS aged between 3 months and 5 
years. Subjects included were newly diagnosed 
cases of WS having two or more of these three 
criteria: infantile epileptic spasms, hypsarrhythmia 
on EEG, and psychomotor retardation/regression. 
Old and previously diagnosed cases of WS, acutely 
sick children, children aged below 3 months and 
above 5 years, and children with cardiac diseases or 
renal failure were excluded from the study. Patients 
without signed consent forms or those provided 
with prior magnesium supplementation within 
3 months were also excluded. Informed written 
consent for inclusion in the study was obtained 
from the patients’ parents or guardians after 
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explaining the procedures and involved risks and 
benefits to them. Ethical clearance was obtained 
from the Ethical Committee of the Institute. 
Detailed clinical history, including patients 
particulars, details of infantile spasms, perinatal and 
neonatal history, developmental history, thorough 
clinical examination, including general-physical 
examinations, anthropometric measurement, and 
detailed central nervous system examination, 
fundus and vision (if required), and follow-up were 
recorded in a predesigned proforma. 
During the follow-up, proforma was updated 
on every visit/interaction with the parents. A 16 
channel sleep EEG was done and neuroimaging 
in the form of magnetic resonance imaging of 
the brain or cranial computerized tomographic 
scan was carried out at the department of 
radiodiagnosis. Also, development quotient/social 
quotient (DQ/SQ) assessment were done at the 
department of psychiatry using standard scales, 
including the developmental screening test (DST)/
the Vineland social maturity scale (VSMS). Serum 
magnesium level estimation was carried out in 
the laboratory of the department of biochemistry 
using the Colorimetric Xylidyl Blue method, and 
the serum magnesium level less than 1.5 mg% was 
considered low. 
The sample size was calculated based on Zou LP et 
al.’s study (2010) (18). Accordingly, the recurrence 
of seizures in patients with WS is reduced by 
75% with magnesium supplementation and by 
50% and type 1 error of 10% (two-tailed) without 
magnesium supplementation. Thus, 25 patients in 
each group were required.
All the enrolled children were randomized into an 
intervention group and a non-intervention group 
using a computer-generated random number table. 
At enrolment, the intervention group received 
daily magnesium sulfate intramuscular injection 
for 3 consecutive days at recommended doses of 
100mg/kg/day once a day (magnesium sulfate 
injection 50% w/v) followed by oral magnesium 
supplementation (children <6 months, 37.5mg/day 
and children >6 months, 75 mg/day) for 3 months 
as a syrup containing magnesium, calcium, and 
vitamin D. However, the non-intervention group 
received syrup containing an equal amount of 
calcium and vitamin D but without magnesium 
(age <6 months: calcium 100 mg/ day + vitamin 
D 100 IU/day; age > 6 months – calcium 200 mg/
day + vitamin D 200 IU/day). Supplementation 
was stopped in children with side effects due 
to magnesium. Both groups received injection 
adrenocorticotropin hormone (ACTH) and 
antiepileptic drugs according to a fixed protocol. 
All the children were followed up in detail at 
least once in 2 weeks up to 3 months of starting 
the treatment. The patients were assessed for 
seizure control and clinical improvement, and the 
proforma was filled at every visit. After 3 months, 
EEG and DQ/SQ were repeated, and the response 
was assessed in the form of EEG improvement, 
improvement in DQ/SQ levels, and the clinical 
response to the treatment. The improvements were 
categorized into three groups: (i) no response 
with <25% frequency reduction in seizures after 
3 months of starting the treatment; (ii) partial 
response with >25% frequency reduction in spasms 
without the occurrence of other types of seizures, 
and (iii) complete response with the total control 
of seizures after 3 months of starting the treatment. 
The data was entered in an MS-Excel worksheet 
and analysed using the Epi info software. The 
mean of frequencies and standard deviations were 
calculated for descriptive data. Also, the chi-square 
test was used for categorical data, and the Student’s 
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t-test was used for continuous data. Moreover, 
the one-way ANOVA test was used to compare 
serum magnesium levels and clinical responses 
to the treatment. A p-value of less than 0.05 was 
considered significant. 
Results
During the study period, 52 patients were recruited, 
and their clinical profiles and demographics 
were studied. The intervention group included 
30 patients, and the non-intervention group 
contained 22 patients. Two of the patients 
were lost during the follow-up, and two of the 
patients were excluded due to side effects from 
magnesium supplementation. Thus, at the end of 
the 3-month follow-up, 48 patients (26 patients in 
the intervention group and 22 patients in the non-
intervention group) remained who were followed 
up and analysed in detail. 
We observed in our cohort that males were 
predominant with the male to female ratio of 
3:1. The most common etiological factor was a 
perinatal insult. Most of the patients belonged to 
middle and low socioeconomic status. Most of 
the patients (63.5%) had flexor type of spasms 
occurring in series, and about one-third of them 
(36.5%) had seizures other than infantile spasms, 
with the most typical type being a generalized 
tonic-clonic seizure. Moreover, about half of the 
patients had microcephaly (48.1%), and about sixty 
percent of children with WS were undernutrition. 
Additionally, most of the patients had cerebral 
palsy, with spastic quadriplegia being the most 
typical type. 
The mean age of onset of spasms was 7.25 ± 6.69 
months, and most of the patients (84.6%) had 
onset of spasms before 12 months of age. Patients 
with WS had DQ on the lower side, with the mean 
being 38.65 ± 15.97. Both groups were comparable 
regarding basic clinical profiles like sex and 
socioeconomic. Serum magnesium levels were 
low in 17 of the patients (35.41%), and the mean 
serum magnesium level was 2.07 ± 0.5 mg/dl. 
We found no significant difference between 
the groups after magnesium supplementation 
regarding clinical response/seizure control 
(p=0.69) and neuro-developmental outcome 
(p=0.09) but observed a significant difference in 
EEG improvement between the groups (p=0.04). 
We also observed that the clinical response was 
better in the intervention group when they had 
normal initial serum magnesium levels compared 
to low initial serum magnesium levels (p=0.003). 
However, we detected no significant difference 
in the non-intervention group regarding the 
clinical response at different serum magnesium 
levels (p=0.418). We also observed that patients 
with normal initial serum magnesium levels had 
complete responses compared to patients with 
low initial serum magnesium levels (p=0.004), 
meaning higher serum magnesium levels yielded a 
better clinical response. We detected no statistically 
significant difference in the response rate between 
the groups with normal initial serum magnesium 
levels. 
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Figure 1. The flow of the study
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Table 1. Baseline characteristics of both groups at the time of recruitment





1. Sex Male 21 15
0.32
Female 5 7
2. Socio-economic status Middle class 19 14
0.48
Lower class 7 8
3. Nutritional status Normal 8 11 0.38
Moderate UN 6 3
Severe UN 12 8
4. Serum Magnesium levels Normal 18 13 0.46
Low 8 9
5. Serum Magnesium levels (mg/dl) Mean ± SD 2.10 ± 0.52 2.04 ± 0.55 0.71
6. Frequency of spasms/day < 5 11 5 0.32
5-10 10 10
>10 5 7










9. Development Quotient < 30 8 7
0.97
30-60 15 12
> 60 3 3
Abbreviations: UN- undernutrition 
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3. DQ/SQ Normal 4 0
0.09Abnormal 22 22
Abbreviations: DQ- development quotient; SQ- social quotient
Table 3. Comparison of clinical response after magnesium supplementation with initial serum levels of magnesium in both groups
Category Serum Magnesium level    Response to treatment  Total p-value
No Partial Complete
Intervention group (n=26) Normal 2 3 13 18 0.003
Low 4 4 0 8
Non-intervention group 
(n=22)
Normal 3 2 8 13   0.42
Low 4 2 3 9
Table 4. Comparison of Clinical response at 3 months with initial serum levels of magnesium
Serum Magnesium levels Seizure control p-value
No response Partial response Complete response
Normal 5 5 21  0.004
Low 8 6 3
Total 13 11 24
Discussion
WS is an age-specific severe epileptic 
encephalopathy. It is characterized by a classical 
clinico-electrical triad, including infantile 
epileptic spasms, regression/arrest of psychomotor 
development, and hypsarrhythmia on EEG, 
although one element may be missing (1). Although 
WS is a well-known syndrome, its treatment is often 
unsatisfactory, and there is no agreement about its 
optimum treatment (19,21). In the last two decades, 
the large progress in the development of newer 
antiepileptic drugs has allowed us to have a vast 
choice of treatment options to control the spasms, 
although they often fail to do so. In our clinic, we 
observed that response to hormonal therapy was 
not as good as described in the western literature. 
Thus, the effect of other possible therapies on WS 
needs to be explored. 
72
Role of Magnesium Supplementation in Children with West Syndrome: A Randomized Controlled Clinical Trial
Iran J Child Neurol. Winter 2022 Vol. 16 No. 1
Studies have reported that magnesium has 
antiepileptic and neuroprotective effects by 
antagonizing excitation through the NMDA 
receptor (14). Studies on the antiepileptic activity 
of magnesium have reported that in patients with 
epilepsy, serum magnesium levels are often low, 
and magnesium supplementation can be used as 
an adjunct to antiepileptic drugs (6-18). Therefore, 
we conducted this open-labeled randomized 
controlled trial to examine the effect of magnesium 
supplementation on children with WS. 
We carried out the present study with a prospective 
enrolment of subjects with a uniform treatment 
protocol and careful follow-up. A minimum 
follow-up period of 3 months was considered, 
and the outcome in the form of clinical response/
seizure control, EEG improvement, and the 
neurodevelopmental outcome was studied in 
those who completed the follow-up. Uniform 
criteria were used for diagnosis, definitions, and 
outcome variables. Standard psychometric tests, 
like DST and VSMS, were used to assess the 
neurodevelopment status of the patients. The study 
comprised of a relatively larger number of patients 
(n=48) compared to other studies (38 children in 
Zou et al.’s study (2010) and 22 children in Carlen 
et al.’s study (2012)) and various case reports 
(16,18). We examined all demographic, clinical, 
and investigative factors that could possibly affect 
the response of the treatment of the children with 
WS.
In the present study, the intramuscular route 
was used in the first 3 days for magnesium 
supplementation followed by oral supplementation 
for 3 months. In a study by Zou et al. (2010), 
the intravenous route was used by giving higher 
doses of magnesium for 3 consecutive weeks. Oral 
supplementation used in this study is much safer 
and easier to administer than supplementation 
through the intravenous route used by Zou et al. 
(2010) (18). 
The clinical profile of WS patients in this study 
was almost similar to that in other Indian studies. 
The mean age of onset of spasms was 7.25 ± 6.69 
months. Perinatal insults, like hypoxic-ischaemic 
encephalopathy (HIE) and neonatal illness, were 
associated  in the most of our patients. The major 
findings of our study regarding neuroimaging were 
diffuse cerebral atrophy and encephalomalacic 
changes due to sequelae to perinatal HIE in 77% 
of the cases. We also observed hypsarrhythmia in 
a relatively small number of the patients. Similar 
results were found by Kalra et al. (2002) and Singhi 
and Ray (2008) (3,20). The present study results 
also indicated that serum magnesium levels were 
low in 17 of the patients (35.41%), and the mean 
serum magnesium level was 2.07 ± 0.5 mg/dl. 
After 3 months of magnesium supplementation, 
no significant difference was found between both 
groups regarding seizure control (p=0.693) and 
neurodevelopmental outcome (P=0.094). However, 
EEG normalization (p=0.003) was significantly 
more in the intervention group compared to the 
control group. Also, within the intervention group, 
seizure control was better in patients with normal 
initial serum magnesium levels than in those with 
low serum magnesium levels (p=0.003). We also 
found that patients with poor clinical response had 
relatively lower initial serum magnesium levels 
(1.73±0.44 mg/dl), which is in line with studies by 
Sinert et al. (2007), Gupta et al. (1994), Oladipo et 
al. (2007), McDonald et al. (1990), and Alan and 
Sander (2012) (6,7,8,14,15). Hypomagnesaemia 
may cause or exacerbate episodes of seizures as 
it has been seen that magnesium is a potential 
modulator of seizure activity that antagonizes 
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excitation through the NMDA receptor and has 
antiepileptic and neuroprotective effects.
We observed that within the intervention group, 
seizures control was significantly better in patients 
with normal initial serum magnesium levels than 
in those with low initial serum magnesium levels. 
However, this difference was not significant in 
the non-intervention group, even with comparable 
serum magnesium levels. This means that 
magnesium supplementation increases serum 
magnesium levels and causes a better clinical 
response with normal serum magnesium levels. 
However, patients with low serum magnesium 
levels might not have a good clinical response. 
This can be explained by the fact that serum 
magnesium in patients with lower levels cannot 
increase to a level where it can effectively act as 
an anticonvulsant with supplementation at the 
dose of present study. Magnesium in our study was 
supplemented at a low dose and used for a shorter 
duration, mainly by the oral route. Thus, further 
studies need to be conducted at higher doses of 
magnesium and by following patients for a longer 
duration and changing the route of administration 
to increase bioavailability. Studies by Carlen et 
al. (2012), Van der Bergh et al. (2011), Zou et al. 
(2010), and Wan et al. (2019) also support that 
supplementing oral/parenteral magnesium causes 
improvement in seizures control (16-18, 22). 
Zou et al. (2010) (18) conducted a randomized 
controlled clinical trial and compared the effect 
of magnesium supplementation in children with 
WS for seizure control and neurodevelopmental 
outcome, as well as for EEG and adverse events. 
They gave higher doses of magnesium (250 mg/
day) intravenously for 3 weeks and assessed 
efficacy after 6 months of follow-up. However, 
we provided a low dose of magnesium, which 
was almost equal to the recommended daily dose. 
We also used the intramuscular route for the 
first 3 days, followed by oral supplementation 
for 3 months. They found that the personal-
social neurodevelopmental outcome significantly 
improved from baseline in the group receiving 
combination treatment (p<0.05). In this study on 
infants with WS, the proportions of seizure-free 
patients from 4 to 24 weeks were significantly 
greater in the intervention group than in the non-
intervention group (91.7% vs. 70%). However, 
in our study, there was no significant difference 
in seizure control and the neurodevelopmental 
outcome between both groups. However, there was 
significant EEG improvement in the intervention 
group than in the non-intervention group. The 
difference in both studies might be since they used 
higher doses of magnesium by the intravenous 
route, which might have been more effective due 
to increased bioavailability, and that they followed 
the patients for a longer duration of 6 months. We 
used the oral route for magnesium supplementation 
after the first 3 days of intramuscular injections, 
which is much safer than continuous intravenous 
injections, and we did not observe any serious 
side effects due to magnesium supplementation. 
However, we used lower doses of magnesium and 
followed the patients for a shorter duration of 3 
months. This might be the reason for the lack of 
significant clinical response in the intervention 
group and the erratic bioavailability of oral 
preparation.
In our study, there was no significant improvement 
in DQ/SQ levels in the intervention group, which 
contradicts the study by Zou et al. (2010) (18). 
They found significant improvement in DQ/SQ 
levels (p<0.05) in the intervention group. Reasons 
may be that most of our patients (>90%) belonged 
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to the symptomatic group and the commonest 
etiology was HIE, which is an irreversible process. 
Another reason might be that we followed our 
patients for a shorter duration of 3 months. 
Although the difference in the DQ/SQ level was 
nearly significant (p= 0.09), the overall long-term 
developmental outcome was not good at all, even 
after the successful treatment of infantile spasms. 
This is in line with Mackay et al.’s study (2004) 
(19) but is in contrast with Zou et al.’s study (2010) 
(18).  
In Conclusion
Although no significant improvement was found 
in seizure control and the neurodevelopmental 
outcome after magnesium supplementation, 
significant EEG improvement was observed. Also, 
within the intervention group, clinical response 
was better in patients with normal initial serum 
magnesium levels than in others. Thus, magnesium 
supplementation may be helpful in children with 
WS. However, more studies are required with a 
higher dose of magnesium supplementation, a 
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